A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

Summary

In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.

Timeline

Start

2021-12-07

Primary completion

2025-06-10

Completion

2025-08-20

Drugs

Indications